Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival ...

But others are forging ahead. Roche has made big bets, acquiring Zealand Pharma’s petrelintide and Carmot Therapeutics’ CT-388, both GLP-1-based drugs, for a combined $8 billion. Early data on ...

Hoffmann-La Roche AG announced a collaboration and licensing agreement with Zealand Pharma to develop and co-commercialize petrelintide. Petrlintide is Zealand’s long-acting amylin analog drug.

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis-based diagnostics unit. The Swiss pharmaceutical and diagnostics giant ...

Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma in March. This therapy is currently undergoing mid-stage clinical trials. Roche's obesity pipeline also ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma (ZELA.CO), opens new tab in March. This therapy is currently undergoing mid-stage clinical trials.

(Reuters) -Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the ...

Roche’s planned facility in North Carolina will create 400 jobs. Credit: jetcityimage via Getty Images. Roche is deepening its manufacturing footprint in the US with plans to invest more than $700m in ...